• CHMP rejects AB Science’s ALS drug pharmatimes
    April 24, 2018
    AB Science’s share price has taken a hit after European Medicine Agency's advisors rejected approval of masitinib for amyotrophic lateral sclerosis.
PharmaSources Customer Service